IBD

Once a gem, now just a rock, Takeda punts PhIII IBD drug as rivals muscle ahead
Once a gem, now just a rock, Takeda punts PhIII IBD drug as rivals muscle ahead
Endpoints
Takeda
IBD
SHP647
Shire
Flag link:
Lilly’s first crowdsourced digital health contest seeks solutions for IBD
Lilly’s first crowdsourced digital health contest seeks solutions for IBD
Fierce Pharma
IBD
Eli Lilly
innovation challenges
innovation
digital health
Flag link:
Microbiome Report for Week Ending 3/9/19
Microbiome Report for Week Ending 3/9/19
CP Wire
microbiome
Synlogic
AOBiome
AbbVie
Infant Bacterial Therapeutics
IBD
atopic dermatitis
Flag link:
Microbiome Report for Week Ending 12/1/18
Microbiome Report for Week Ending 12/1/18
CP Wire
microbiome
Evelo Biosciences
Kaleido Biosciences
Vedanta Biosciences
psoriasis
atopic dermatitis
IBD
Flag link:
Microbiome Report for Week Ending 12/1/18
Evelo Biosciences
Kaleido Biosciences
Vedanta Biosciences
psoriasis
atopic dermatitis
IBD
Flag link:
Vedanta pockets $12M from Johnson & Johnson on start of microbiome drug trial
Vedanta pockets $12M from Johnson & Johnson on start of microbiome drug trial
Fierce Biotech
Vedanta Biosciences
JNJ
microbiome
IBD
VE202
Flag link:
Rebiotix and Microbiome Insights Collaborate on a Microbiome IBD Diagnostic Tool to Aid Clinical Development
Rebiotix and Microbiome Insights Collaborate on a Microbiome IBD Diagnostic Tool to Aid Clinical Development
CP Wire
Microbiome Insights
Rebiotix
IBD
diagnostics
microbiome
Flag link:
Rebiotix and Microbiome Insights Collaborate on a Microbiome IBD Diagnostic Tool to Aid Clinical Development
Microbiome Insights
Rebiotix
IBD
diagnostics
microbiome
Flag link:
Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout
Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout
Enpoints
Takeda
Shire
inflammatory bowel disease
IBD
ulcerative colitis
Crohn's Disease
M&A
SHP647
Flag link:
Landos Biopharma Initiates Ph I Trial of First-in-class Oral Treatment for IBD
Landos Biopharma
ulcerative colitis
Chron's Disease
IBD
BT-11
Flag link:
Microbiome startup Nextbiotix raises €7M to tackle inflammatory bowel diseases
Microbiome startup Nextbiotix raises €7M to tackle inflammatory bowel diseases
Fierce Biotech
Nextbiotix
inflammatory bowel disease
IBD
microbiome
Flag link:
Genentech signs $534M deal with Microbiotica to search gut bacteria for IBD targets, new drugs
Genentech signs $534M deal with Microbiotica to search gut bacteria for IBD targets, new drugs
Fierce Biotech
Genentech
Microbiotica
microbiome
IBD
biomarkers
Flag link:
CytoReason Cements Proof-of-Concept with Machine-Learning-Facilitated Biomarker Breakthrough in Inflammatory Bowel Disease
CytoReason Cements Proof-of-Concept with Machine-Learning-Facilitated Biomarker Breakthrough in Inflammatory Bowel Disease
CP Wire
CytoReason
IBD
inflammatory bowel disease
biomarkers
Flag link:
CytoReason Cements Proof-of-Concept with Machine-Learning-Facilitated Biomarker Breakthrough in Inflammatory Bowel Disease
CytoReason
IBD
Flag link:
Takeda teams with Cedars Sinai on tech tool to personalize IBD treatment choices
Takeda teams with Cedars Sinai on tech tool to personalize IBD treatment choices
Fierce Pharma
drug marketing
Takeda
Cedars Sinai
IBD
mobile apps
Flag link:
With help from J&J, upstart Provention lands rights to two mid-stage IBD drugs and shoots for PhII
With help from J&J, upstart Provention lands rights to two mid-stage IBD drugs and shoots for PhII
Endpoints
JNJ
Provention Bio
IBD
inflammatory bowel disease
PRV-6527
Crohn's Disease
PRV-300
ulcerative colitis
Flag link:
Synergy Pharmaceuticals begins Phase Ib trial of SP-333
Synergy Pharmaceuticals begins Phase Ib trial of SP-333
Yahoo/Fly on the Wall
SP-333
Synergy Pharmaceuticals
IBD
inflammatory bowel disease
Flag link:
IND Submission by Synergy Pharma
IND Submission by Synergy Pharma
Yahoo/Zacks
Synergy Pharmaceuticals
SP-333
IBD
inflammatory bowel disease
Flag link: